Mercury Bio Appoints Casey Perkins as New Chief Business Officer Driving Biotech Innovation

Mercury Bio's New Strategic Leader: Casey Perkins

In a significant move within the biotechnology sector, Mercury Bio has announced the promotion of Cassandra "Casey" Perkins to the role of Chief Business Officer (CBO), effective June 22, 2026. With a focus on advancing treatments for neurodegenerative diseases such as Alzheimer’s and Parkinson’s, Perkins’ elevation underscores both her impressive contributions to the company and the importance of her role in steering future initiatives.

A Journey of Success

Joining Mercury Bio in December 2025, Perkins quickly established herself as a pivotal figure by leading the company’s business development and corporate strategy efforts. Her strategic acumen is evident in the partnerships she has forged with key pharmaceutical players, attracting both investors and collaborators while meticulously overseeing the operational aspects of the company's preclinical programs. This promotion is a reflection of her accomplishments and her integral presence in the company's leadership as Mercury Bio prepares to transition its technologies to clinical settings.

Recognized recently by CIO Views Magazine as one of the Top 10 Empowering Women Leaders to Follow in 2026, Perkins boasts over 25 years of extensive experience in the biotechnology and pharmaceuticals arenas. Her expertise spans commercial strategy, market accessibility, and patient service operations across various challenging fields including rare diseases, genetics, and immunology, with an emphasis on neurology and oncology.

Transformative Impact in Biotech

Throughout her illustrious career, Perkins has had a role in the commercialization of numerous pioneering therapies. Notably, she contributed to ZOLGENSMA®, which is a groundbreaking gene therapy designed for treating spinal muscular atrophy in infants under the age of two. Beyond her professional endeavors, Perkins is also a founding member of the American Biotech Innovation Alliance (ABIA), further cementing her influence in the biotech community.

Bruce McCormick, CEO and Co-Founder of Mercury Bio, praised Perkins' swift adaptation and her essential role in refining the company's strategy: "Casey came in and quickly recognized as a trusted partner by our investors, partners, and the entire team. Her keen insights have been vital for guiding Mercury Bio towards critical IND-enabling work and beyond. She collaborates closely with our Chief Scientific Officer, Dr. Richard Sayre, and other strategic partners to propel forward our preclinical work effectively."

As Perkins steps into her role, she does so amid significant events in the biotechnology landscape. The 2026 BIO International Convention in San Diego is just around the corner, presenting crucial opportunities for networking with potential partners and investors. Additionally, she prepares for an upcoming critical presentation on intracellular medicine associated with neurodegenerative diseases at the 3rd Annual Cell & Gene Therapy Conference in Boston.

About Mercury Bio

Mercury Bio stands as a leader in the immunology-driven biotechnology space, focusing on the development of intracellular therapies aimed at combating neurodegenerative diseases. Bolstered by a robust intellectual property portfolio and strategic collaborations with leading research entities, the company is advancing a pipeline specifically targeting disorders like Parkinson’s and Alzheimer’s while cultivating strong partnerships throughout the biopharmaceutical sector.

With Casey Perkins at the helm of business operations, Mercury Bio is poised for exciting developments that could reshape the future of treatment for neurodegenerative diseases, ensuring that their innovative solutions reach those in need.

In this rapidly evolving field, the leadership and vision of professionals like Perkins serve as cornerstones for success, instilling hope and potential for countless individuals affected by these debilitating conditions.